Eric S. Benevich
Net Worth

Last updated:

What is Eric S. Benevich net worth?

The estimated net worth of Mr. Eric S. Benevich is at least $37,456,600 as of 15 Apr 2024. He owns shares worth $5,415,726 as insider, has earned $26,050,234 from insider trading and has received compensation worth at least $5,990,640 in Neurocrine Biosciences, Inc..

What is the salary of Eric S. Benevich?

Mr. Eric S. Benevich salary is $748,830 per year as Chief Commercial Officer in Neurocrine Biosciences, Inc..

How old is Eric S. Benevich?

Mr. Eric S. Benevich is 60 years old, born in 1965.

What stocks does Eric S. Benevich currently own?

As insider, Mr. Eric S. Benevich owns shares in one company:

Company Title Shares Price per share Total value
Neurocrine Biosciences, Inc. (NBIX) Chief Commercial Officer 40,778 $132.81 $5,415,726

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

NBIX logo
NBIX
Neurocrine Biosciences, Inc.
$132.81

Eric S. Benevich insider trading

Neurocrine Biosciences, Inc.

Mr. Eric S. Benevich has made 42 insider trades between 2017-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 69,521 units of NBIX stock on 14 Mar 2024. As of 15 Apr 2024 he still owns at least 40,778 units of NBIX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 7,231 $81.49 $589,254
Option
Non-Qualified Stock Option 12,587 $81.05 $1,020,176
Option
Common Stock 12,587 $81.05 $1,020,176
Sale
Common Stock 12,587 $133.37 $1,678,665
Option
Non-Qualified Stock Option 7,231 $81.49 $589,254
Sale
Common Stock 69,521 $139.38 $9,689,767
Option
Non-Qualified Stock Option 69,521 $81.05 $5,634,677
Option
Common Stock 5,479 $79.02 $432,951
Option
Common Stock 69,521 $81.05 $5,634,677
Option
Non-Qualified Stock Option 5,479 $79.02 $432,951
Sale
Common Stock 21,857 $134.69 $2,943,876
Option
Non-Qualified Stock Option 53,143 $43.24 $2,297,903
Option
Non-Qualified Stock Option 21,857 $79.02 $1,727,140
Option
Common Stock 21,857 $79.02 $1,727,140
Option
Common Stock 53,143 $43.24 $2,297,903
Sale
Common Stock 1,098 $133.02 $146,050
Sale
Common Stock 1,207 $140.78 $169,926
Sale
Common Stock 1,600 $107.4 $171,837
Sale
Common Stock 980 $104.12 $102,036
Sale
Common Stock 15,360 $102.42 $1,573,233
Sale
Common Stock 2,030 $102.29 $207,643
Sale
Common Stock 1,280 $105.63 $135,201
Sale
Common Stock 1,207 $109.95 $132,711
Option
Non-Qualified Stock Option 400 $43.24 $17,296
Option
Common Stock 400 $43.24 $17,296
Sale
Common Stock 400 $125 $50,000
Option
Common Stock 22,162 $41.78 $925,928
Option
Non-Qualified Stock Option 7,775 $35.99 $279,822
Option
Common Stock 20,063 $43.24 $867,524
Sale
Common Stock 20,063 $125.9 $2,525,972
Option
Common Stock 7,775 $35.99 $279,822
Option
Non-Qualified Stock Option 20,063 $43.24 $867,524
Sale
Common Stock 100 $125.36 $12,536
Option
Common Stock 100 $41.78 $4,178
Option
Non-Qualified Stock Option 100 $41.78 $4,178
Option
Common Stock 24,593 $41.78 $1,027,496
Option
Non-Qualified Stock Option 24,593 $41.78 $1,027,496
Sale
Common Stock 24,593 $125.33 $3,082,314
Option
Common Stock 8,968 $41.78 $374,683
Option
Non-Qualified Stock Option 8,968 $41.78 $374,683
Sale
Common Stock 8,968 $125.02 $1,121,179
Sale
Common Stock 400 $125 $50,000
Option
Non-Qualified Stock Option 400 $41.78 $16,712
Option
Common Stock 400 $41.78 $16,712
Sale
Common Stock 4,960 $110.82 $549,682
Sale
Common Stock 980 $79.67 $78,073
Sale
Common Stock 2,030 $80.83 $164,081
Sale
Common Stock 809 $80.68 $65,269
Sale
Common Stock 1,280 $80.78 $103,398
Sale
Common Stock 5,628 $89.62 $504,393
Sale
Common Stock 4,270 $116.83 $498,868
Sale
Common Stock 809 $114.03 $92,247
Option
Non-Qualified Stock Option 300 N/A N/A
Option
Common Stock 300 N/A N/A
Sale
Common Stock 400 N/A N/A
Sale
Common Stock 2,257 N/A N/A
Sale
Common Stock 20,595 N/A N/A
Option
Non-Qualified Stock Option 20,595 N/A N/A
Option
Common Stock 20,595 N/A N/A
Sale
Common Stock 2,257 N/A N/A
Sale
Common Stock 1,934 N/A N/A
Sale
Common Stock 8,632 N/A N/A
Sale
Common Stock 2,030 N/A N/A
Sale
Common Stock 1,395 N/A N/A
Sale
Common Stock 1,954 $103.01 $201,276
Sale
Common Stock 1,954 N/A N/A
Sale
Common Stock 5,835 N/A N/A
Sale
Common Stock 920 N/A N/A
Sale
Common Stock 1,357 N/A N/A
Sale
Common Stock 12,350 N/A N/A
Sale
Common Stock 820 N/A N/A
Sale
Common Stock 132 N/A N/A
Sale
Common Stock 821 N/A N/A